Efficacy and tolerability of pharmacotherapy for post-stroke depression: a network meta-analysis

• DOI: 10.18632/oncotarget.23891
• Publication Date: 2018-01-04T08:07:18Z
• Authors: Linghui Deng; Shi Qiu; Yan Yang; Lu Wang; Yuxiao Li; Jing Lin; Qiang Wei; Lu Yang; Deren Wang; Ming Liu
• Keywords: Tolerability; Reboxetine; Paroxetine; Discontinuation; Citalopram; Escitalopram

Post-stroke depression (PSD) occurs in approximately one third of stroke survivors, leading to great disability and mortality. As there is no consensus on the optimal pharmacological treatment for PSD, we aimed evaluate relative efficacy tolerability available interventions.We did a network meta-analysis incorporate evidence from relevant trials providing direct indirect comparisons. We searched PubMed, Cochrane Library Central Register Controlled Trials, Embase reference lists articles up March, 2017 randomized controlled (RCTs), different pharmacotherapies PSD. For analysis, primary outcome was mean change Hamilton Depression Scale (HAMD) score between baseline endpoint. presented by discontinuation any reason. This study registered with PROSPERO, number CRD42016049049.From total 869 citations, 15 RCTs 876 participants were included. 13 drugs considered. efficacy, paroxetine ranked best HAMD reduction, followed imipramine, reboxetine, nortriptyline, citalopram fluoxetine at end treatment. However, duloxetine 4-week 8-week duration reduction. tolerability, but significant result comparisons.Paroxetine probably option consider patients To get quicker relief depression, might be useful its rapid onset antidepressant action. The comparable among all antidepressants. But more high-quality are needed.